ST香雪：橘红痰咳液将启动慢阻肺临床研究

证券之星12-03

证券之星消息，ST香雪(300147)12月02日在投资者关系平台上答复投资者关心的问题。

投资者提问：京东健康拥有庞大线上流量与医药供应链，贵公司现有橘红痰咳液等呼吸类成熟产品可通过此次慢阻肺关爱中心直接触达患者。请问该合作目前对成熟产品的销量是否已产生实际拉动？后续是否有针对现有在售产品的专项推广计划，以快速兑现合作红利？

ST香雪回复：您好，公司橘红痰咳液改良型新药开发项目，适应症为慢性阻塞性肺疾病，将启动临床研究。新药研发的进展会按照信披规则结合实际情况对外披露，请您留意公司公告。谢谢！

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2588620046?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-03 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588620046","market":"fut","top_or_hot":-1,"title":"ST香雪：橘红痰咳液将启动慢阻肺临床研究","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/300147\">ST香雪</a>(300147)12月02日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：<a href=\"https://laohu8.com/S/06618\">京东健康</a>拥有庞大线上流量与医药供应链，贵公司现有橘红痰咳液等呼吸类成熟产品可通过此次慢阻肺关爱中心直接触达患者。请问该合作目前对成熟产品的销量是否已产生实际拉动？后续是否有针对现有在售产品的专项推广计划，以快速兑现合作红利？</p><p>ST香雪回复：您好，公司橘红痰咳液改良型新药开发项目，适应症为慢性阻塞性肺疾病，将启动临床研究。新药研发的进展会按照信披规则结合实际情况对外披露，请您留意公司公告。谢谢！</p><p>以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ST香雪：橘红痰咳液将启动慢阻肺临床研究</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nST香雪：橘红痰咳液将启动慢阻肺临床研究\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-03 20:48 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2025120300037022.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，ST香雪(300147)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：京东健康拥有庞大线上流量与医药供应链，贵公司现有橘红痰咳液等呼吸类成熟产品可通过此次慢阻肺关爱中心直接触达患者。请问该合作目前对成熟产品的销量是否已产生实际拉动？后续是否有针对现有在售产品的专项推广计划，以快速兑现合作红利？ST香雪回复：您好，公司橘红痰咳液改良型新药开发项目，适应症为慢性阻塞性肺...</p>\n\n<a href=\"https://stock.stockstar.com/RB2025120300037022.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://stock.stockstar.com/RB2025120300037022.shtml","article_id":"2588620046","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588620046","pubTimestamp":1764766105,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，ST香雪12月02日在投资者关系平台上答复投资者关心的问题。新药研发的进展会按照信披规则结合实际情况对外披露，请您留意公司公告。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300147":"ST香雪","BK0239":"医药制造","BK0060":"抗癌","BK0028":"国家队","BK0070":"员工持股"},"translate_title":"ST Xiangxue: Orange Red Phlegm Cough Liquid will start clinical research on COPD","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300147":1.5},"content_text":"证券之星消息，ST香雪(300147)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：京东健康拥有庞大线上流量与医药供应链，贵公司现有橘红痰咳液等呼吸类成熟产品可通过此次慢阻肺关爱中心直接触达患者。请问该合作目前对成熟产品的销量是否已产生实际拉动？后续是否有针对现有在售产品的专项推广计划，以快速兑现合作红利？ST香雪回复：您好，公司橘红痰咳液改良型新药开发项目，适应症为慢性阻塞性肺疾病，将启动临床研究。新药研发的进展会按照信披规则结合实际情况对外披露，请您留意公司公告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588620046","isCrawlerRequest":true}